...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Apollo Therapeutics: Funding of Four Initial Projects and Operational Update

| Print |
Wednesday, 22 February 2017 10:00 (UTC + 1)

ApolloTX logo

  • First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities
  • Recruited highly experienced Project Directors with track records of delivering project success within big pharma
  • More than £8.5m committed to projects so far from a total budget of £40m

Stevenage, UK, February 22, 2017 / B3C newswire / --Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first of its drug discovery programmes in collaboration with academics at each of its partner universities.

Apollo Therapeutics was established in January 2016 by AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge.  It supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases.

After evaluating initial opportunities across all three universities, Apollo has approved funding for and launched its first four drug discovery projects:

  • A small molecule discovery programme to treat alpha1 antitrypsin deficiency, a genetic disorder affecting the lungs and liver, with Dr Ravi Mahadeva, University of Cambridge and Addenbrooke’s Hospital
  • A cell therapy for the treatment of retinal degeneration, which is a major cause of vision loss and blindness, with Prof Astrid Limb and Prof Sir Peng Khaw at the UCL Institute of Ophthalmology
  • A small and large molecule discovery programme for the treatment of pulmonary arterial hypertension,  a condition affecting the cardiovascular system, with Prof Martin Wilkins and Prof Lan Zhao, Imperial College London
  • A project to enhance the efficacy and persistence of autologous and in vivo T-cell therapies, with Prof Randall Johnson, University of Cambridge

These initial projects represent novel and compelling drug discovery projects, emerging from academic research in areas of high medical need for which Apollo’s Drug Discovery Team saw a clear route to value creation. A total of £8.5m has been committed in milestoned project plans.Two further projects are currently being finalised, with multiple others in the evaluation process across all three academic institutions. 

The recruitment of the Drug Discovery Team Project Directors is now complete with Dr Paul Hamblin, Dr Darren Cawkill and Dr Nadine Clemo accepting positions under the leadership of CEO, Dr Richard Butt. 

Bringing more than 60 years’ combined experience to running and delivering projects within industry, across a variety of technology platforms and therapy areas, the team is well positioned to work with academic scientists to identify drug targets and design innovative drug discovery programmes through key milestones for potential future licensing.

Apollo’s collaborative model is working well with its technology transfer partners – Cambridge Enterprise, Imperial Innovations and UCL Business – providing valuable support in sourcing opportunities from within their respective academic institutions. Industry partners AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation are also contributing both expertise and internal resources to enable project evaluation and execution.

Dr Richard Butt, CEO of Apollo Therapeutics, commented: “The diversity of these four initial projects illustrates the breadth and quality of opportunity we are seeing from our partner universities, both in disease area and therapeutic modality.  The participation and support of all six partners is excellent, in the spirit of this collaborative venture and the unique Apollo model.”

Dr Ian Tomlinson, Chairman of Apollo Therapeutics commented: “The level of engagement with both the academic community and industry players is enabling the Drug Discovery Team to deliver Apollo’s vision of funding novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.“


About Apollo Therapeutics

Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation).  It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry.  Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success.
Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.


Contacts

Instinctif Partners
Sue Charles/Rozi Morris
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)20 7457 2020